Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial - Summary - MDSpire
Advertisement
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial
To evaluate the systemic exposure of delgocitinib cream 20 mg/g in adults with severe Chronic Hand Eczema (CHE) under maximal use conditions and compare it with systemic exposure in adults with atopic dermatitis, particularly focusing on differences in application amounts and body surface area.
Key Findings:
Delgocitinib cream 20 mg/g resulted in minimal systemic exposure in adults with severe CHE, even under maximal use conditions, suggesting a favorable safety profile.
Adults with moderate to severe atopic dermatitis showed low systemic exposure despite applying nearly 10 times more cream than those with CHE, underscoring the formulation's effectiveness in limiting absorption.
The formulation of delgocitinib cream limits systemic absorption, indicating unlikely pharmacological effects from topical applications, which is crucial for patient safety.
Interpretation:
The findings suggest that delgocitinib cream can be safely used in adults with severe CHE without significant systemic absorption, supporting its favorable safety profile and potential as a first-line topical treatment option.
Limitations:
The study focused on a specific population (adults with severe CHE) and may not be generalizable to other demographics or conditions, which could limit the applicability of the findings.
The comparison with atopic dermatitis patients may not fully account for differences in disease severity and body surface area involvement, potentially skewing the results.
Conclusion:
Delgocitinib cream 20 mg/g demonstrates minimal systemic absorption in adults with severe CHE, indicating its potential as a safe topical treatment option.
by Melinda Gooderham, Christopher G. Bunick, JiaDe Yu, Douglas Maslin, Shannon K. R. Schneider, Marie Louise Østerdal, Anders Søhoel, Daniel Elenius Madsen, Lawrence F. Eichenfield
